UN Integrated Regional Information System - March 26, 2009

In the Thibela TB study, one of the largest of its kind, almost 40,000 gold miners in South Africa received a nine-month course of isoniazid, a standard first-line TB drug. None of the miners was actually suffering from TB, but the high prevalence of both HIV and silicosis in South African mines makes miners extremely vulnerable to the disease.

Isoniazid preventive therapy (IPT) is usually given to people living with HIV to reduce their risk of developing TB, but the Thibela study is testing the theory that treating an entire community with the drug could have a significant impact on TB rates for a period of about 10 years.

The study, which is being conducted in three of the country's nine provinces, is only expected to conclude in 2012, but preliminary findings released on Wednesday suggest that isoniazid has already been effective in reducing TB incidence among participants.

"We've had very few subsequent infections in those taking the preventative treatment," said Dr Dave Clark, deputy CEO of the Aurum Institute, the health research NGO conducting the study.

The results could also influence case management of HIV-positive people in South Africa, who are around 20 times more likely to develop TB than those who are HIV-negative - 75 percent of new TB patients are HIV-positive.

The World Health Organization (WHO) has recommended IPT for people living with HIV in countries with a high prevalence of TB, but less than one percent of HIV-positive people in South Africa are receiving it, according to Clark.

Although many feared the preventative treatment would increase the incidence of drug-resistant TB, the number of such cases in the study has been negligible. Most patients also showed a surprising wiliness to adhere to treatment.

"Asking mineworkers, who are ostensibly well, to adhere to treatment is difficult," Clark said. "We've had an 80 percent success rate to date with adherence, and it's caught on. We've had cases where workers have asked, 'Is this something we can take back to our communities, to our wives?'"

Findings from the study might also influence the way health workers and policy-makers handle epidemics other than TB. "If this methodology can work in this setting, there is huge potential that the approach would work in the case of other diseases, such as diabetes and hypertension," said Clark.

In the latest global TB control report released by WHO on Tuesday, South Africa's incidence of TB ranks second only to Swaziland's, the highest in the world. South Africa also has the world's fourth highest burden of multidrug-resistant (MDR) TB.

090326
IR090320

Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980 – 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .